|
Program Overview:
The studies covered in this webcast will explore two main topics related to comparisons of cardiac surgery and percutaneous cardiovascular procedures. The first topic the panel will address is the comparison of transcatheter versus surgical aortic valve replacement in high risk patients from the PARTNER trial at 2 years. The second topic is a comparison of long-term outcomes between patients receiving coronary artery bypass surgery and percutaneous coronary intervention in the ACERT matched comparison of patients from the NCDR and STS registries.
Click Here to access this CME Program
|
|
Release Date:
May 7, 2012
|
| |
Expiration Date:
November 7, 2012 |
| |
Estimated Time:
1 hour |
|
Program Overview:
The studies covered in this webcast will explore two main topics. First, new insights into the relative risks and benefits of various adjunctive pharmacological agents in the treatment of Acute Coronary Syndromes and ST-segment Elevation Myocardial Infarction. Specifically, the panel will address the route of Abciximab delivery in the treatment of STEMIs in the INFUSE-AMI trial. The panelists will then discuss the administration of Cilostazol Versus Double Dose Clopidogrel after PCI with a drug-eluting stent in the HOST ASSURE trial. The second topic the panelists will discuss is the on-going debate regarding elective PCI performed at hospitals without on-site cardiac surgery in the CPORT-E trial.
Click Here to access this CME Program
|
|
Release Date:
May 7, 2012
|
| |
Expiration Date:
November 7, 2012 |
| |
Estimated Time:
1 hour |
|
|
Program Overview:
This webcast will review the progress made with DES, the problems that remain, and describe the new approaches to further improve long-term outcomes for patients undergoing PCI. Drug-eluting coronary stents (DES) have dramatically reduced the rates of restenosis, recurrent ischemia and repeat procedures for patients with coronary artery disease compared to bare metal stents. However, the first generation of metallic DES with permanent polymers introduced new complications, including delayed healing, positive vessel remodeling and malapposition, leading to very late stent thrombosis and late restenosis. Newer DES with permanent polymers have reduced but not eliminated these concerns. Future DES are under development that release the drug from a small amount of a bioabsorbable polymer, or without any polymer at all. Fully bioabsorbable DES are also being developed.
Click Here to access this CME Program
|
|
Release Date:
March 12, 2012
|
| |
Expiration Date:
September 12, 2012 |
| |
Estimated Time:
1 hour |
|
|
Program Overview:
Join an international faculty of 11 leading FH specialists, cardiologists and lipidologists as they participate in a forum called the iQ&A interactive Medical Intelligence Zone for Familial Hypercholesterolemia. This global panel will analyze, answer and discuss 70+ FAQs addressing clinical dilemmas and therapeutic advances for patients with familial hypercholesterolemia
Click Here to access this CME Program
|
|
Release Date:
April 30, 2012
|
| |
Expiration Date:
April 30, 2014 |
| |
Estimated Time:
4 hours |
|
|
Program Overview:
The faculty will discuss data from important late breaking clinical studies presented at the recent annual scientific sessions of American Heart Association (AHA) 2011 in Orlando, FL. This learning activity aims to provide a background and context for the presentation of these new data so that learners will be able to prepare to assimilate this data into their clinical practice.
Click Here to access this CME Program
|
|
Release Date:
January 9, 2012
|
| |
Expiration Date:
June 9, 2012 |
| |
Estimated Time:
1.0 hour |
|
|
Program Overview:
The faculty will discuss late breaking data from important late breaking clinical studies presented at the recent Transcatheter Cardiovascular Therapeutics scientific symposium in San Francisco, CA. This learning activity aims to provide a background and context for the presentation of these new data so that learners will be able to prepare to assimilate this data into their clinical practice.
Click Here to access this CME Program
|
|
Release Date:
January 9, 2012
|
| |
Expiration Date:
June 9, 2012 |
| |
Estimated Time:
1.0 hour |
|
|
Program Overview:
This program addresses the educational need to enhance understanding of the clinical risks and benefits of these new agents. With new guidelines for the management of PCI published by the American College of Cardiology (ACC) and American Heart Association (AHA) in early 2008, the precise application of evidence-based therapy has the potential to improve clinical outcomes for patients undergoing PCI and stenting.
Click Here to access this CME Program
|
|
Release Date:
December 15, 2011
|
| |
Expiration Date:
June 15, 2012 |
| |
Estimated Time:
1.5 hours |
|
|
Program Overview:
A national panel of cardiology experts, led by A. Michael Lincoff, MD, of the Cleveland Clinic, looks at glucose regulation, insulin resistance, and lipid modification as part of an overall strategy for reducing cardiovascular risk in the setting of diabetes and acute coronary syndrome.
Click Here to access this CME Program
|
|
Release Date:
December 7, 2011
|
| |
Expiration Date:
December 7, 2013 |
| |
Estimated Time:
2.5 hours |
|
|
Program Overview:
Deepak Bhatt, MD, of Harvard Medical School, leads a national panel of experts reviewing the latest antithrombotic interventions in high risk ACS, with a focus on novel anticoagulation strategies in the setting of PCI. They ask the questions, “Where Are The Science, Data, and Clinical Trials Taking Us?”
Click Here to access this CME Program
|
|
Release Date:
December1, 2011
|
| |
Expiration Date:
December1, 2013 |
| |
Estimated Time:
2.5 hours |
|
|
Program Overview:
This symposium will review the wide spectrum of myocardial ischemia from diagnosis to management. An emphasis will be placed on ischemia as evaluated pre- and post-revascularization. An overview will be provided of the multiple pathophysiological characteristics and how they may affect patient outcomes, including myocardial viability, preprocedural ischemia, and plaque composition. The concept of vulnerable plaque and its consequences will be discussed. The importance of complete revascularization will be reviewed and compared to incomplete revascularization. The management of the later will be discussed with introduction of the RIVER-PCI study.
Click Here to access this CME Program
|
|
Release Date:
December 1, 2011
|
| |
Expiration Date:
June 1, 2012 |
| |
Estimated Time:
1.0 hour |
|
|
Program Overview:
The faculty will discuss late breaking data from important late breaking clinical studies presented at the recent annual scientific sessions of Transcatheter Cardiovascular Therapeutics (TCT) 2011 in San Francisco, CA. This learning activity aims to provide a background and context for the presentation of these new data so that learners will be able to prepare to assimilate this data into their clinical practice.
Click Here to access this CME Program
|
|
Release Date:
November 30, 2011
|
| |
Expiration Date:
May 30, 2012 |
| |
Estimated Time:
1.0 hour |
|
|
Program Overview:
Herzel Gerstein, MD, of McMaster University, leads a national panel of experts in reviewing the role of early insulin therapy for optimizing cardiovascular risk reduction across the dysglycemic continuum for type 2 diabetes. A close look at what the landmark outcome trials teach us about cardioprotection in the diabetic patient.
Click Here to access this CME Program
|
|
Release Date:
November 28, 2011
|
| |
Expiration Date:
November 28, 2013 |
| |
Estimated Time:
2.5 hours |
|
|
Program Overview:
The most comprehensive multimedia CME resource for SPAF. The “Best and the Brightest” address the trickiest and toughest questions, issues and clinical dilemmas in stroke prevention in Atrial Fibrillation.
Click Here to access this CME Program
|
|
Release Date:
November 28, 2011
|
| |
Expiration Date:
November 28, 2013 |
| |
Estimated Time:
6.0 hours |
|
|
Program Overview:
The landscape of interventional cardiology is changing and clinicians and their institutions need to be prepared. The future of the industry involves a multidisciplinary approach to patient care. As the patient population ages and present with comorbidities and more complex multivessel disease teams need to provide an integrated protocol to complication management and patient care. Of equal importance is creating a procedural environment that facilitates and encourages a team approach.
Click Here to access this CME Program
|
|
Release Date:
December 1, 2011
|
| |
Expiration Date:
May 31, 2012 |
| |
Estimated Time:
1.0 hour |
|
|
Program Overview:
Distinguished presenter Gerald V. Naccarelli, MD, Professor of Medicine and Chief, Division of Cardiology at Penn State Heart and Vascular Institute, examines risk stratification and pharmacologic management strategies for optimizing rhythm control for patients with new onset atrial fibrillation.
Click Here to access this CME Program
|
|
Release Date:
February 28, 2011
|
| |
Expiration Date:
February 28, 2013 |
| |
Estimated Time:
2.0 hours |
|
|